Presentation and management of docetaxel-related adverse effects in patients with breast cancer

Cancer Manag Res. 2014 May 27;6:253-9. doi: 10.2147/CMAR.S40601. eCollection 2014.

Abstract

The taxane chemotherapeutic agent docetaxel has been utilized in the management of breast cancer in the adjuvant, neoadjuvant and metastatic setting. Although well tolerated by the majority of patients, docetaxel toxicity may limit the dose which can be administered. Adverse events include infusion reactions, febrile neutropenia, fatigue, fluid retention, pneumonitis, cutaneous and nail toxicity, epiphora and lacrimal duct stenosis, gastrointestinal complications, and neuropathies. In this review, we explore these complications and how they can be effectively managed to improve patient quality of life during and following docetaxel therapy.

Keywords: adverse events; chemotherapy; toxicity.

Publication types

  • Review